The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. Mayo Clinic researchers aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite sequencing was performed on DNA extracted from 18 HCC and 35 control tissues. A phase I plasma pilot incorporated quantitative allele-specific real time target and signal amplification assays on independent plasma-extracted DNA from 21 HCC cases and 30 cirrhotic controls. A phase II plasma study was then performed in 95 HCC cases, 51 cirrhosis controls, and 98 healthy controls using target enrichment long-probe quantitative amplified signal (TELQAS) assays. Based on the results, novel MDMs identified in this study proved to accurately detect HCC via plasma testing. Further optimization and clinical testing of this promising approach are indicated. The study was published in Case Reports in Hepatology.